Vor Biopharma Inc.

Last updated September 27, 2026
Favorite this organization

Organization details

Legal name
Vor Biopharma Inc.
Ownership
Public
Status
Active
SIC code
2836 — Biological Products, (No Diagnostic Substances)
Headquarters city
Boston
Headquarters state / province
Massachusetts
Headquarters country
United States
Fiscal year end
December
Ticker symbol
VOR
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001817229
EIN
81-1591163

Board of directors

Follow this board

Chief executives

Robert Ang · President and CEO
Dates unknown
Jean-Paul Kress · CEO and Chairman
Since June 2025

Director election results

Annual meeting of June 11, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

11 of this board's directors also sit on 34 other boards.

Network of Vor Biopharma Inc.'s board connections Climb Bio Inc. Climb Bio Inc. Jade Biosciences Inc. Jade Biosciences Inc. PepGen Inc. PepGen Inc. Sionna Therapeutics Inc. Sionna Therapeutics In... Solid Biosciences Inc. Solid Biosciences Inc. ARS Pharmaceuticals Inc. ARS Pharmaceuticals In... Acrivon Therapeutics Inc. Acrivon Therapeutics I... Acumen Pharmaceuticals Inc. Acumen Pharmaceuticals... Artiva Biotherapeutics Inc. Artiva Biotherapeutics... Bicara Therapeutics Inc. Bicara Therapeutics In... Black Diamond Therapeutics Inc. Black Diamond Therapeu... Evommune Inc. Evommune Inc. Freenome Inc. Freenome Inc. Hemab Therapeutics Holdings Inc. Hemab Therapeutics Hol... Janux Therapeutics Inc. Janux Therapeutics Inc... LENZ Therapeutics Inc. LENZ Therapeutics Inc. Alexander Cumbo Alexander Cumbo Andrew David Levin Andrew David Levin Joshua Resnick Joshua Resnick Peter Kolchinsky Peter Kolchinsky Rajeev M. Shah Rajeev M. Shah Vor Biopharma Inc.
Shared director Other board Same sector +18 more in the list below

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$0
0 purchases by 0 insiders
Sold, last 12 months
$98,936,479
72 sales by 5 insiders
Date Insider Transaction Shares Price Value
Aug 24, 2026 RA CAPITAL MANAGEMENT, L.P. 10% owner Option exercise +1,500 $3.74 $5,604
Jul 16, 2026 RA CAPITAL MANAGEMENT, L.P. 10% owner In-the-money exercise +2,100,000 $0.00 $4,200
Jul 16, 2026 RA CAPITAL MANAGEMENT, L.P. 10% owner Open-market sale −213 $19.75 $4,207
Apr 22, 2026 Rajeev M. Shah Director, 10% owner Open-market sale −165,150 $15.77 $2,604,416
Apr 20, 2026 RA CAPITAL MANAGEMENT, L.P. Director, 10% owner Open-market sale −171,963 $15.77 $2,711,857
Apr 17, 2026 RA CAPITAL MANAGEMENT, L.P. Director, 10% owner Open-market sale −458,411 $16.28 $7,462,931
Apr 15, 2026 RA CAPITAL MANAGEMENT, L.P. Director, 10% owner Open-market sale −53,644 $16.01 $858,840
Apr 14, 2026 RA CAPITAL MANAGEMENT, L.P. Director, 10% owner Open-market sale −153,735 $15.97 $2,455,148
Apr 13, 2026 RA CAPITAL MANAGEMENT, L.P. Director, 10% owner Open-market sale −530,610 $16.15 $8,569,352
Apr 10, 2026 Rajeev M. Shah Director, 10% owner Open-market sale −828 $15.75 $13,041
Apr 9, 2026 Rajeev M. Shah Director, 10% owner Open-market sale −135,201 $16.59 $2,242,985
Apr 8, 2026 Rajeev M. Shah Director, 10% owner Open-market sale −353,242 $16.32 $5,764,909
Apr 8, 2026 Rajeev M. Shah Director, 10% owner Open-market sale −130,862 $16.91 $2,212,876
Apr 6, 2026 Peter Kolchinsky Director, 10% owner Open-market sale −537,754 $16.51 $8,878,319
Apr 6, 2026 Peter Kolchinsky Director, 10% owner Open-market sale −44,728 $17.31 $774,242

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.